Rising Dragon Acquisition Corp. (RDAC)

Rising Dragon Acquisition Corp. (NASDAQ: RDAC) is a blank-check company. That is the official name for what the market calls a SPAC — a shell company that goes public with a pile of cash, then uses that money to merge with or buy an operating business. The idea is simple. The company raises capital from investors, typically C$50 million or so, lists on the stock exchange, and then has a window of time — usually two to three years — to find a target company and do a deal. If it succeeds, the target company becomes public as a result. If it fails to find a partner, it returns the money to investors and shuts down.

What a blank-check company actually is

Rising Dragon is not an operating business. It has no employees, no facilities, no revenue, and no products. It is a legal shell. What it has is cash — the C$50 million it raised in its October 2024 initial public offering, when it sold five million units to investors at C$10 per unit. Each unit consisted of one ordinary share and a “right” entitling the holder to receive one-tenth of another share if the company completes a merger.

The rationale for SPACs appeals to a particular kind of investor and entrepreneur. A traditional Initial Public Offering, where an operating company goes public directly, is expensive and time-consuming. The company must hire investment banks, auditors, and lawyers. It must file voluminous disclosure documents, roadshow to institutional investors, and satisfy years of regulatory requirements. The whole process costs tens of millions and takes over a year. A SPAC is the opposite. The shell company goes public quickly and cheaply — it is already a public shell, registered and ready — and then seeks a merger partner. In theory, the target company avoids some of the cost and complexity of a traditional IPO because the vehicle is already public.

But SPACs have a dark side. The shell is controlled by the sponsor — the management team and their backers — who took the company public and now have a deadline to find a deal. As the deadline approaches, the pressure to “do a deal” (any deal) can overtake the discipline to do a good deal. Target companies know the sponsor’s desperation and may negotiate hard-to-favorable terms. And investors in the original SPAC — those who bought the units in the IPO — often see their shares diluted as part of the merger consideration flows to the target company’s sellers.

The deal: HZJL and the business-combination plan

Rising Dragon announced its intended acquisition target in late 2024: HZJL Cayman Limited, a company that provides business solutions and services, reportedly focused on technology and consulting work. The deal structure assigns HZJL an equity value of C$350 million, with an additional “earn-out” of up to 20 million shares contingent on revenue hitting certain targets over the next two years. An earn-out is a risk-transfer mechanism: the sellers of HZJL get upside if their projections prove accurate, and downside if reality disappoints.

The merger was originally scheduled to close by July 15, 2026. In May 2026, Rising Dragon sought to extend that deadline, proposing to push the business-combination deadline to October 15, 2027 — a full additional year — through a series of one-month extensions if needed. This extension request is typical of SPACs wrestling with unforeseen delays, regulatory hurdles, or simple slowness in execution. Investors in Rising Dragon’s original IPO faced a choice: go along with the extension and hope the merger succeeds, or opt out and reclaim their original investment (in theory — in practice, depending on the terms, they may have some losses).

Geography and business focus

The company’s name and structure — a Cayman Islands-incorporated shell pursuing a China-based target — reflect exposure to mainland Chinese business and regulatory risk. HZJL is based in China and provides technology and consulting services, areas where Chinese companies have grown rapidly. However, U.S. and Canadian regulators have become more cautious about Chinese ownership of technology-adjacent businesses, and geopolitical tension between North America and China has created uncertainty around approvals and long-term openness to Chinese-controlled enterprises trading on U.S. exchanges.

The deal terms also contemplate that HZJL’s management and operations remain China-focused — the target is not a North American company seeking capital, but a Chinese company seeking a public listing on a North American exchange. That geographic and regulatory asymmetry carries specific risks: Chinese companies face capital controls, regulatory changes, and compliance requirements that create uncertainty for Western shareholders.

The SPAC economics for investors

Here is how the economics work. An investor who bought Rising Dragon’s units at the IPO in October 2024 paid C$10 per unit for one share and one-tenth of a right. When (and if) the merger closes, those shares and rights convert into shares of the merged company — the newly public version of HZJL. But the investor is now diluted. The sponsor (management) received shares for free when the SPAC went public; some of those shares were placed with the sponsor at a 20% discount to the IPO price. And the HZJL sellers receive new shares and the earn-out contingent shares as their merger consideration. The result: the SPAC’s original public investors end up owning a smaller percentage of the merged company than they thought.

Many SPAC deals destroy value for early investors. The dynamics are well-documented. The sponsor benefits from completed deals (they retain their founders’ shares) whether the deal is good or bad. The SPAC’s original investors bear the dilution risk. And the target company’s sellers often drive hard bargains, knowing the sponsor’s desperation to “get a deal done.”

Some SPAC mergers work — they result in a genuine operating business that goes public and trades successfully. But others merge, see the stock price decline over time, and leave original SPAC investors in a loss position. There is no inherent magic to the SPAC structure. It is simply a vehicle, and the success of any SPAC’s outcome depends entirely on the quality of the deal negotiated, the business fundamentals of the target, and luck.

Risks and what to watch

Rising Dragon’s principal risk is execution risk on the HZJL merger. If the merger fails, investors lose the opportunity cost and may see the shell company liquidate and return capital — but not without losses to fees and timing delays. If the merger succeeds, the risk transfers to HZJL’s business fundamentals and growth trajectory. Investors should ask: What exactly does HZJL do? Who are its customers? How durable are its contracts? Are the revenue targets in the earn-out realistic, or inflated?

Regulatory risk is another vector. U.S. regulators have become scrutinous of Chinese-controlled companies trading on Nasdaq, and the Committee on Foreign Investment in the United States (CFIUS) reviews deals that might create national-security concerns. An unexpected regulatory challenge could derail or reshape the deal.

There is also timing risk. The SPAC window closes in 2027. If Rising Dragon and HZJL cannot finalize their deal by then, the SPAC may be forced to liquidate or renegotiate on less favorable terms.

How to research Rising Dragon and SPAC mergers

Investors interested in Rising Dragon should begin with the company’s SEC filings (CIK 0002018145) and track the Form 8-K announcements related to the HZJL merger. The proxy statement filed in advance of the shareholder vote on the merger will contain detailed financials and risk disclosures for HZJL, along with management projections and the deal terms.

Key questions: What is HZJL’s actual business (beyond the marketing description)? Who are its largest customers, and how long are their contracts? What are HZJL’s recent financial results, and how realistic are the earn-out revenue targets? What is the governance structure post-merger — who owns how much, and who controls the board?

For anyone considering investing in a SPAC merger, it is worth reading at least one comprehensive post-mortem of failed SPAC deals to understand the structural incentives at play. SPACs are not inherently bad, but they are not inherently good either — they are structures with known failure modes. Investor due diligence is essential.